NCT00600496 2025-11-13A Phase I, Open-Label, Multi-center Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD6244 (ARRY-142886)AstraZenecaPhase 1 Active not recruiting140 enrolled
NCT00030498 2013-01-16Erlotinib in Treating Patients With Solid Tumors and Liver or Kidney DysfunctionNational Cancer Institute (NCI)Phase 1 Completed75 enrolled